Igmesine (JO-1784) is a sigma receptor agonist. It has neuroprotective and antidepressant effects in animal studies as well as nootropic effects in models of age-related cognitive decline. It showed good results in phase I human clinical trials but has not been continued further.
This page contains content from the copyrighted Wikipedia article "Igmesine"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.